Canakinumab in a subgroup of patients with COVID-19
- 3 June 2020
- journal article
- letter
- Published by Elsevier BV in The Lancet Rheumatology
- Vol. 2 (8), e457-ee458
- https://doi.org/10.1016/s2665-9913(20)30167-3
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19New England Journal of Medicine, 2020
- Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort studyThe Lancet Rheumatology, 2020
- Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular DiseaseCirculation Research, 2020
- Clinical course and mortality risk of severe COVID-19The Lancet, 2020
- Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASCThe FASEB Journal, 2019
- Glyburide inhibits the Cryopyrin/Nalp3 inflammasomeThe Journal of cell biology, 2009
- The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritisRheumatic Disease Clinics of North America, 2004